|
RA Treatment For The Future: Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
A fusion protein, cytotoxic T-lymphocyte–associated antigen 4–IgG1 (CTLA4Ig), is the first in a new class of drugs known as costimulation blockers being evaluated for the treatment of rheumatoid arthritis. Preliminary study results indicate CTLA4Ig may be effective for the treatment of RA
Source: About.com
For more Information:
|
